Literature DB >> 32919020

Polymorphisms in matricellular SPP1 and SPARC contribute to susceptibility to papillary thyroid cancer.

Xuan Su1, Bo-Heng Xu2, Da-Lei Zhou2, Zu-Lu Ye2, Hui-Chan He3, Xin-Hua Yang2, Xiao Zhang2, Qing Liu2, Jiang-Jun Ma2, Qiong Shao2, An-Kui Yang4, Cai-Yun He5.   

Abstract

There is a compelling need to identify novel genetic variants for papillary thyroid cancer (PTC) susceptibility. The Cancer Genome Atlas (TCGA) data showed associations between SPP1 and SPARC mRNA overexpression and aggressive behaviors of PTC, which prompted us to assess potential associations between genetic variants in these genes and PTC risk. Three highly linked SPARC loci (rs1054204, rs3210714, and rs3549) contributed to reduced PTC risk under a codominant model (odds ratio [OR], 0.79-0.80). Variant CAG alleles at these loci significantly enhanced SPARC transcription activation upon cotransfection with miR-29b and miR-495 when compared to the common alleles GGC (all P < 0.05). The three SPARC polymorphisms interacted with SPP1 rs4754, with elevated joint ORs of 2.43, 2.52, and 2.52, respectively. Additionally, interaction between SPP1 rs2358744 and SPARC rs2304052 was observed. Our study revealed associations between SPP1 and SPARC polymorphisms that, individually or in combination, are involved in PTC susceptibility.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Genetic model; Papillary thyroid cancer; Single nucleotide polymorphism; Susceptibility

Year:  2020        PMID: 32919020     DOI: 10.1016/j.ygeno.2020.09.018

Source DB:  PubMed          Journal:  Genomics        ISSN: 0888-7543            Impact factor:   5.736


  2 in total

1.  Predicting Non-Alcoholic Fatty Liver Disease Progression and Immune Deregulations by Specific Gene Expression Patterns.

Authors:  Fanhong Zeng; Yue Zhang; Xu Han; Min Zeng; Yi Gao; Jun Weng
Journal:  Front Immunol       Date:  2021-01-26       Impact factor: 7.561

2.  Comprehensive Analysis to Identify SPP1 as a Prognostic Biomarker in Cervical Cancer.

Authors:  Kaidi Zhao; Zhou Ma; Wei Zhang
Journal:  Front Genet       Date:  2022-01-04       Impact factor: 4.599

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.